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AFMOritavancin, a lipoglycopeptide with marked bactericidal activity against vancomycin-resistant Staphylococcus
aureus and enterococci, induces calcein release from CL:POPE and POPG:POPE liposomes, an effect enhanced by
an increase in POPG:POPE ratio, and decreasedwhen replacing POPGbyDPPG (Domenech et al., BiochimBiophys
Acta 2009; 1788:1832–40). Using vesicles prepared from lipids extracted from S. aureus, we showed that
oritavancin induces holes, erosion of the edges, and decrease of the thickness of the supported lipid bilayers
(atomic force microscopy; AFM). Oritavancin also induced an increase of membrane permeability (calcein
release) on a time- and dose-dependent manner. These effects were probably related to the ability of the drug to
bind to lipid bilayers as shown by 8-anilino-1- naphthalene sulfonic acid (ANS) assay. Interaction of oritavancin
with phospholipids at the level of their glycerol backbone and hydrophobic domain was studied by monitoring
changes of Laurdan excitation generalized polarization (GPex) and 1,6-diphenyl-1,3,5-hexatriene (DPH)
ﬂuorescence anisotropy upon temperature increase. Oritavancin increased GPex values and the transition
temperature, indicating a more ordered structure at the level of the glycerol backbone. Oritavancin slightly
decreased DPH ﬂuorescence depolarization intensities, suggesting an increase in ﬂuidity at the level of acyl
chains. Together, our data conﬁrm the interaction of oritavancin with lipids and the potential role of a rigidifying
effect at the level of glycerol backbone for membrane permeabilization. This work shows how AFM and
biophysical methods may help in characterizing drug–membrane interactions, and sheds further light on the
mode of action of oritavancin.+32 2 764 73 73.
(M.-P. Mingeot-Leclercq).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The bacterial envelope fulﬁls several functions essential for survival
such as maintenance of cell shape, resistance to turgor pressure, and
coordinated cell growthanddivision. It alsoacts as amolecular sieve and
plays an important role in molecular recognition and cellular interac-
tions. Because of these functions and of marked differences in
composition from the envelope of eukaryotic cells, the bacterial
envelope stands as a desirable drug target [1]. Thus, a large number of
antibiotics acting on peptidoglycan, such as β-lactams and glycopep-
tides, have been successfully brought in clinical use sincemany years. In
contrast, and with the exception of nisin (used as food preservative),
molecules acting on the membrane part of the bacterial envelope have
remained ill developed for many years. This is now changing rapidly,
because of the increased resistance manifested by bacteria towards β-lactams, glycocopeptides, and several other classes of antibacterials.
Starting from the naturally occurring polymyxins [2] and lipoptaibols
[3,4], several investigators have synthesized fatty acid conjugates of
various peptides or proteins such as cathepsins G [5], lactoferrin [6,7],
magainins [8], or, in the context of antiparasitic chemotherapy, a
cecropin-melittin hybridpeptide [9]. Another approachhas been to start
from existing antibiotics and to construct amphipathic derivatives, such
as those made from aminoglycosides [10,11] or glycopeptides [12,13].
Among the latter, telavancin and oritavancin show remarkable
bactericidal activity towards Gram-positive bacteria, related, at least in
part, to their selective membrane destabilization properties [14,15].
These have now reached an advanced level of clinical development for
the treatment of severe infections caused by multiresistant Staphylo-
coccus aureus [16].
Oritavancin is of particular interest in this context because it shows
activity not only against S. aureus resistant to β-lactams (so-called
“methicillin-resistant S. aureus” [MRSA]), but also against Enterococci
and S. aureus that have become resistant to vancomycin bymodiﬁcation
of the D-Ala-D-Ala motif in nascent peptidoglycan [17], and to which
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Oritavancin is also active against bacteria in stationary phase, including
bioﬁlms [15,20]. This suggests a mode of action largely independent
from the biosynthesis of the bacterial envelope, in contrast to β-lactams
[21] and vancomycin [22].
Two key structural features distinguishing oritavancin from
vancomycin are a chloro-biphenyl methylene side chain and an
epivancosamine moiety (see structures in [23]). Together, these
confer a marked amphipathic character to the molecule [12]. While
the consequences of these changes on the membrane effects caused
by oritavancin are not entirely known, recent work has demonstrated
the capacity of the drug to disrupt membrane potential and to
increase the permeability of liposomes composed of binary mixture of
lipids [23]. In this model, oritavancin causes rapid and complete
release of calcein from CL:POPE liposomes, and slower but still
substantial release from POPG:POPE liposomes. This effect is concen-
tration-dependent, is enhanced by an increase in POPG:POPE ratio,
and is decreased when POPG is replaced by DPPG. AFM of CL:POPE
supported bilayers also showed that oritavancin causes a remodeling
of the lipid domains combined with a redisposition of the drug and
degradation of the borders. In all these studies, vancomycin, at the
concentrations examined in these studies, was without signiﬁcant
effect [23].
The intrinsic activity and the speciﬁcity of drugs that target lipids
are, however, related to deﬁned structures and arrangements [24,25],
which can be critically dependent upon the global lipid content. It is,
therefore, important to characterize the capacity of oritavancin to
interact with lipids using models that are as relevant as possible to
bacterial membranes. In the present study, supported lipid bilayers
and liposomes were prepared from lipids extracted from S. aureus.
Supported lipid bilayers were used to characterize, by atomic force
microscopy, the effect of oritavancin on the nanoscale lipid organi-
zation. Using liposomes (large unilamellar vesicles [LUV]), we
measured the effect of oritavancin on membrane permeabilization
using calcein as a probe and determined the binding of 8-anilino-1-
naphthalene sulfonic acid (ANS) on liposomes incubated with
oritavancin. We also characterized the effect of oritavancin on the
polar head group region and the hydrocarbon core using 6-
dodecanoyl-2-dimethylaminonaphthamene (Laurdan) and , 6-diphe-
nyl-1,3,5-hexatriene (DPH), respectively. Finally, to further explore
the speciﬁc role of the main lipids found in membranes of S. aureus,
we investigated these two last parameters on liposomes composed of
synthetic lipids (LysylDOPG:POPG:POPE and CL:POPE). Vancomycin
was used as a comparator in all these studies.
2. Materials and methods
2.1. Materials
The ATCC25923 S. aureus strain (laboratory standard; fully suscep-
tible to both β-lactams [MSSA] and vancomycin)was used in this study.
Beef heart cardiolipin (CL; disodium salt; purityN99%), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol (POPG), 1,2-dioleoyl-sn-glycero-
3-[phospho-rac-(3-lysyl-(1-glycerol))], HCl (Lysyl-DOPG), and 1-pal-
mitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) were pur-
chased from Avanti Polar Lipids (Alabaster, AL) and used without
further puriﬁcation. Calcein was purchased from Sigma-Aldrich (St.
Louis,MO) andwas puriﬁed as described previously [26]. Brieﬂy, calcein
was dissolved in 6 N NaOH and subjected to size-exclusion chromatog-
raphy through a Sephadex® LH-20 column. The ﬁnal concentration of
calcein solution in 20 mM Tris–HCl was 73 mM with an osmolality of
434 mOsm/kg (measured by the freezing point technique, using a
model 3C2 Advanced Cryomatic Osmometer [Advanced Instruments,
Needham Heights, MA]). ANS (8-anilino-1- naphthalene sulfonic acid),
DPH (1,6-diphenyl-1,3,5-hexatriene), and Laurdan (6-dodecanoyl-2-
dimethyl-aminonaphthalene) were purchased from Molecular Probes(Invitrogen, Carlsbad, CA) and used without further puriﬁcation.
Oritavancin diphosphate powder was supplied by Targanta Therapeu-
tics (Cambridge, MA; presently The Medicines Company, Parsippany,
NJ), as microbiological standard for in vitro investigations. It was
dissolved in water containing 0.002% polysorbate-80 (vol:vol), accord-
ing to the manufacturer's instructions and the recommendations of the
Clinical and Laboratory Standard Institute [27], to prevent adhesion to
plastic surfaces [28]. For this reason, all effects of oritavancin were
studied, and are presented in comparison with liposomes exposed to
0.002% polysorbate-80 alone. Vancomycin was obtained from Glax-
oSmithKline s.a. (Genval, Belgium) as the product registered for paren-
teral use in humans and complyingwith the provisions of the European
Pharmacopeia (vancomycin–HCl; no excipient). The minimal concen-
trations of oritavancin and vancomycin that inhibit the growth of
vancomycin-susceptible S. aureus (MIC) are typically around 0.04 and
0.69 μM (0.064 and 1 mg/L), respectively, and the concentrations at
which bactericidal effects are observed (minimal bactericidal concen-
trations [MBC; 3 log10 decrease in colony forming units [cfus]) are
around 0.11 μM and 5.5 μM (0.2 and 8 mg/L) [29,30].
2.2. Extraction of lipids from S. aureus
Lipids were extracted using a modiﬁed Bligh and Dyer method to
prevent the degradation of lysylphosphatidylglycerol into phosphati-
dylglycerol. Brieﬂy, bacteria were grown in Mueller Hinton Broth until
exponential phase (OD=0.6, λ=620 nm). They were collected by
centrifugation at 3,000×g for 15 min and washed three times by
resuspending the pellet in 10 mM Tris–HCl, pH 3.0. Extraction steps
included: (a) the addition of 1.5 mLof CHCl3-CH3OH(2:1, v/v) to0.4 mL
of the bacterial suspension and vigorous vortexing for 5 min; (b) the
addition of 0.5 mL of CHCl3 and 5 min vortexing; (c) the addition of
0.5 mL of 10 mM Tris–HCl, pH 3.0 and 5 min vortexing; (d) a centri-
fugation (1000×g, 5 min) to allow separation between the organic and
aqueous phases. The organic phase was collected and dried, and the
extracted lipids were resuspended in CHCl3-CH3OH (2:1, v/v) and
stored at−20 °C in a N2 atmosphere.
2.3. Large unilamellar vesicles preparation
The solvent (CHCl3:CH3OH [2:1, v/v]) in which lipids (extracted or
synthetic) were dissolved, was evaporated using a Rotavapor system
(model R-210, Buchi Labortechnik AG, Flawil, Switzwerland). Dried
ﬁlmsweremaintainedunder reduced pressure overnight and thereafter
hydrated with 20 mM Tris–HCl, 150 mM NaCl, 20 mM CaCl2 pH 7.4 for
AFMstudies,with the puriﬁed calcein for permeability experiments and
with 10 mM Tris–HCl, pH 7.4 for the experiments with ANS, DPH and
Laurdan. Large Unilamellar Vesicles (LUV) were obtained after 5 cycles
of freeze/thawing and 10 cycles of extrusion in a 10 mL Thermobarrel
Extruder (Lipex Biomembranes, Vancouver, Canada) under a nitrogen
pressure of 10 bars through two polycarbonate ﬁlters of 100 nm or
400 nmpore size for ﬂuorescence studies and AFM studies, respectively
(Nucleopore, Costar Corporation, Badhoevedorp, The Netherlands).
Non-entrapped calcein was removed using minicolumn centrifugation.
As reported in literature, large unilamellar vesicles with diame-
terN40 nm exhibit an equal distribution of lipid across the membrane.
The size and polydispersity of liposome suspensionsweremonitored by
quasi-elastic light scattering with a Zetasizer Nano SZ (Malvern
Instruments,Worcestershire, UK). Lipid concentration on the liposomal
suspensionswasmeasured byphosphorousquantiﬁcation aspreviously
described [31].
2.4. Atomic force microscopy
Before each experiment, the contact mode cell was extensively
washed with ethanol and water. Mica squares (0.25 cm2) were glued
onto a steel disc, cleaned carefully with water before use and cleaved
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of vesicles (S. aureus lipid extraction in 20 mM Tris–HCl, 150 mM
NaCl, 20 mM CaCl2, pH 7.4), was deposited on the mica surface and
incubated for 1 h at room temperature. This method involved
liposome fusion which did not allow to control the lipid asymmetry.
The sample was thereafter washed with buffer (20 mM Tris–HCl,
150 mM NaCl, pH 7.4) to eliminate non-adsorbed vesicles. AFM
contact mode images in liquid were obtained using a Nanoscope IV
Multimode AFM (Veeco Metrology Group, Santa Barbara, CA) with
triangular Si3N4 cantilevers (Microlevers, Veeco Metrology Group,
Santa Barbara, CA.) with a nominal spring constant of 0.01 N × m−1.
The instrument was equipped with a “J” scanner (120 μm). To
minimize the applied force on the sample the set point was con-
tinuously adjusted during imaging. Images were acquired at 90º scan
angle with a scan rate of 2 Hz. All images were processed using the
Veeco software.
2.5. Permeability studies
Membrane permeabilization was followed by monitoring the
leakage of entrapped, self-quenched calcein from liposomes upon
measuring the increase of ﬂuorescence signal subsequent to its
dilution in the external medium [32]. The liposome total phospholipid
concentration was adjusted to a ﬁnal concentration of 5 μM with
isoosmotic buffer (20 mM Tris–HCl, 200 mM NaCl, pH 7.4). After
overnight storage at 4 °C, liposomes were exposed to the drug under
study at 37 °C at the desired concentration and for the suitable time
with continuous stirring and protection from light. All ﬂuorescence
determinations were performed on an LS 55 ﬂuorescence spectro-
photometer (Perkin-Elmer Ltd., Beaconsﬁeld, UK) using λexc and λem
of 476 nm and 512 nm, respectively, and slits ﬁxed at 3 nm. The
percentage of calcein released under the inﬂuence of drug was
deﬁned as [(Ft-Fcontr)/(Ftot-Fcontr)]×100, where Ft is the ﬂuorescence
signal measured at time t in the presence of drug, Fcontr is the
ﬂuorescence signal measured at the same time in the absence of drug,
and Ftot is the total ﬂuorescence signal obtained after complete
disruption of liposomes by Triton X-100 at a ﬁnal concentration of 2%
(checked by quasi-elastic light spectroscopy).
2.6. Binding experiments
Drug interactions with lipids were assessed using a ﬂuorescence-
based assay using ANS. This negatively charged, ﬂuorescent probe has
a low ﬂuorescence yield in polar environments, which is greatly
enhanced when it interacts with lipids. ANS was dissolved at ﬁnal
concentration of 5 mM in methanol. The liposome total phospholipid
concentration was adjusted to a ﬁnal concentration of 50 μM with
10 mM Tris–HCl pH 7.4. The experiments consisted of incubating
liposomes with the drugs (60 nM) for 60 min at 37 °C. The samples
were then titrated with ANS and ﬂuorescence was monitored. All
ﬂuorescence determinations were performed on an LS 55 ﬂuores-
cence spectrophotometer (Perkin-Elmer Ltd., Beaconsﬁeld, UK) using
λexc and λem of 380 nm and 480 nm, respectively and slits ﬁxed at
5 nm. The fraction of bound ANS was calculated using Eq. (1):
ANS½ b =
Fb−F0
Ab−A0
ð1Þ
where Fb and F0 are theﬂuorescence intensities of ANSwith andwithout
lipid in the cuvette and Ab and A0 are the emission coefﬁcients of ANS in
presence and absence of lipid, respectively. Emission coefﬁcients in
presence of lipid were determined as the slope in the graphic
representation of the ﬂuorescence emission intensity at high lipid
concentration (1–2 mM) as a function of low ANS concentration (0.1–
1 μM) [33]. Concentration of bound ANS ([ANS]b) as a function of theconcentration of the free ANS ([ANS]free) was adjusted to a Langmuir
isotherm Eq. (2):
ANS½ b = Cmax
ðK· ANS½ FreeÞb
1 + ðK· ANS½ FreeÞb
ð2Þ
where Cmax is the maximum concentration of ANS bound to lipids, K is
the binding constant and b is a parameter that gives information of the
cooperativity of the process.
The variation of the surface potential in the membranes caused by
drug incorporation was determined using the values of the different K
obtained from Eq. (2) and introducing them in Eq. (3).
ΔΨ=
RT
F
ln
K
K0
 
ð3Þ
where R, T and F are the universal constant of gases, the temperature
and the Faraday constant, respectively; K and K0 are the apparent
association constants obtained in the sampleswith andwithout drugs,
respectively [34,35].
2.7. Laurdan generalized polarization studies
The effect of drugs on the gel-liquid crystalline phases of the
phospholipids at the level of glycerol backbone was determined by
monitoring the temperature dependence of Laurdan excitation gener-
alized polarization. Laurdan is a polarity sensitive probe [36], located at
the glycerol backbone of the bilayer with the lauric acid tail anchored in
the phospholipid acyl chain region [37]. We monitored the bilayer
ﬂuidity-dependent ﬂuorescence spectral shift of Laurdan due to dipolar
relaxation phenomena. Upon excitation, the dipole moment of Laurdan
increases noticeably and water molecules in the vicinity of the probe
reorient around this newdipole.When themembrane is in aﬂuid phase,
the reorientation rate is faster than the emission process and,
consequently, a red-shift is observed in the emission spectrum of
Laurdan. When the bilayer packing increases part of the water
molecules is excluded from the bilayer and the dipolar relaxation of
the remaining water molecules is slower, leading to a ﬂuorescent
spectrum which is signiﬁcantly less shifted to the red [38].
Fluorescence determinations were carried out using a thermo-
stated Perkin-Elmer LS55 ﬂuorescence spectrophotometer at an
excitation wavelength of 340 nm. The lipid concentration of lipo-
somes was adjusted to 100 μM with 10 mM Tris–HCl, pH 7.4 and
Laurdan was added from a 5×10−3M stock solution of DMF to give a
lipid:probe ratio of 300. Drugs were added to liposomes to a ﬁnal
concentration of 60 nM and incubated under continuous agitation at
37 °C out of light for 60 min. Generalized polarization (GP) from
emission spectra was calculated using Eq. (4):
GPex =
I440−I490
I440 + I490
ð4Þ
where I440 and I490 are the ﬂuorescence intensities at emission
wavelengths of 440 nm (gel phase) and 490 nm (liquid crystalline
phase), respectively, at a ﬁxed excitation wavelength of 340 nm.
GPex values as a function of temperature were adjusted to a
Boltzmann Eq. (5):
GPex¼ GP2ex +
GP1exGP2ex
1 + exp
Tm−T
m
  ð5Þ
where GPex1 and GPex2 are the maximum and minimum values of GPex,
Tm the melting temperature of the composition studied and m is the
slope of the transition that gives information of the cooperativity of
the process.
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The inﬂuence of drugs on the phase behavior of the hydrocarbon
domain of the bilayer was followed by monitoring the dependence of
the degree of DPH polarization degree over temperature. DPH is
thought to reside in the hydrophobic core of the membrane [39–41].
For pure phospholipids, the characteristic shape of the plot is
sinusoidal, with a plateau of high anisotropy values at temperatures
below Tm, another plateau of low anisotropy values at temperature
above Tm, and a sharp transition of anisotropy values in a short range
of temperatures whose averaged value correspond to Tm. Tm is
strongly dependent on the natural dynamicmotions of the bilayer and
shift of its values are indicative of changes of the ordering in domains
where the probe is located. DPHwas dissolved to a ﬁnal concentration
of 100 μM in tetrahydrofuran and incorporated to the sample with the
lipids before evaporation to a molar ratio 300:1 (lipid: DPH). The total
phospholipid concentration of each preparation was adjusted to a
ﬁnal value of 50 μM with 10 mM Tris–HCl, pH 7.4. Drugs (60 nM)
were incubated for 60 min at 37 °C with liposomes in the dark.
Anisotropy (r) of samples was determined as a function of the
temperature. All ﬂuorescence determinations were performed on an
LS 55 ﬂuorescence spectrophotometer using λexc and λem of 381 nm
and 426 nm, respectively and slits ﬁxed at 5 nm. r values were
determined as shown in Eq. (6):
r =
IVV  G⋅IVH
IVV + 2⋅G⋅IVH
ð6Þ
were IVV is the ﬂuorescence intensity when angle between polarizers
is 0 °, IVH is the ﬂuorescence intensity when angle between polarizers
is 90 °, and G is an inherent factor to the ﬂuorometer used. Data
obtained were adjusted to a Boltzmann Eq. (7) as:
r = r2 +
r1−r2
1 + exp
Tm−T
m
  ð7Þ
where r1 and r2 are the maximum andminimum values of anisotropy,
Tm the melting temperature of the composition studied, and m the
slope of the transition that gives information of the cooperativity of
the process.
2.9. Statistical analysis
All statistical analyses were performed under GraphPad Prism
version 4.3 for Windows (GraphPad Software, San Diego, CA) using
two-way ANOVA using all data points for the comparison between
plots or F-test when only Tm values were compared.
3. Results
3.1. Changes in bilayer morphology and thickness (AFM imaging)
AFM allows visualizing in real time the surface of cells or lipid
membranes as they interact with external agents [42]. We have thus
examined the effect of vancomycin and oritavancin on the topography
of supported bilayers prepared from lipids extracted from S. aureus
(Fig. 1). Due to the complex nature of the composition of S. aureus
lipids (nearly 90–95% of charged phospholipids), the extension, and,Fig. 1. Nanoscale membrane activity of vancomycin (left) or oritavancin (right) on
supported bilayers prepared from lipids extracted from S. aureus. AFM height images
(5 μm×5 μm; z-scale: 20 nm) of supported planar bilayer recorded prior (0 min) or
after exposure for 20, 40, 60 and 80 min to vancomycin (5.5 μM [8 mg/L]) (left) or
oritavancin (84 nM [0.15 mg/L]) (right). Vertical cross-sections were taken along the
position indicated by the continuous line (shown in the 80 min panels). Black arrows
showed holes induced by oritavancin.consequently, the covering of the mica surface by the lipids, were
different from one experiment to another. The supported bilayers,
nevertheless, presented the same roughness and step height.
Fig. 3. Release of calcein from liposomes made of lipids extracted from S. aureus upon
exposure at 37 °C to vancomycin (squares; closed symbols) or oritavancin (circles; open
symbol). Top: effect of concentration after 8 h contact. The vertical arrows (markedMBC)
point to the minimal bactericidal concentrations (3 log10 cfu decrease) of vancomycin
(dotted line) or oritavancin (solid line) towards S. aureus ATCC 25923; note that the scale
for vancomycin [VAN] extends from 0 to 60 μM and from 0 to 600 nM for oritavancin
[ORI]). Bottom: effect of time at a ﬁxed concentration (vancomycin: 36 μM; oritavancin:
360 nM). The ordinate shows the percentage of calcein released compared to what was
observed after addition of 2% Triton X-100. Each value is the mean of 3 independent
experimental determinations±SEM.
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not induce major effect during the time of the experiment (left
panels). In contrast, oritavancin (tested at 0.15 mg/L [84 nM] in
0.002% polysorbate, corresponding to MBC) induced the appearance
of holes already after 20 min, and the edges of the supported bilayers
were progressively eroded with time (right panels). Also, streaky
features were seen in the images, presumably reﬂecting lipid material
rearranged upon interaction with the drug. The thickness, obtained by
comparing the step height in Fig. 1 between the top of the lipid layer
(brightest region) to the uncovered mica (darkest region) was
measured over an 80 min period after initial contact. This thickness
decreased only slightly (from 5.5±0.3 to 4.9±0.2 nm) over the
observation period when the lipid bilayers were incubated with
vancomycin, but more rapidly and more markedly in the presence of
oritavancin (from 5.7±0.4 to 3.5±0.2 nm) (Fig. 2).
3.2. Permeabilization of bilayers (release of calcein)
Since holes and decrease of the thickness appeared in the
supported bilayers incubated with bactericidal concentrations of
oritavancin but not with vancomycin, we compared the abilities of
the two drugs to permeabilize lipid bilayers. This was assessed by
following the release of calcein entrapped at self-quenching concen-
trations within liposomes prepared from lipids extracted from
S. aureus. Fig. 3 shows the results obtained as a function of the drug
concentration (upper panel) and of time of exposure (lower panel).
Whatever its concentration (0–60 μM) and the duration of the incu-
bation (0–24 h), vancomycin did not cause calcein release. In contrast,
oritavancin, caused both a concentration- and time-dependent release
of the probe. Of interest, this release became clearly detectable once
the concentration had exceeded about twice the MBC of oritavancin
and tended to reach a plateau at about 5- to 6-fold this concentration
(upper panel). It also proceeded almost linearlywith timeover theﬁrst
6 h with a tendency to a plateau thereafter (lower panel).
To avoid destabilization of the bilayers, and to compare oritavancin
and vancomycin at the same molar concentration, all subsequent
experiments were performed at a drug concentration of 60 nM
(oritavancin: 0.11 mg/L; vancomycin: 0.09 mg/L).
3.3. Binding to lipids (change in 8-anilino-1-naphthalene sulfonic acid
[ANS] ﬂuorescence)
To determine the capacity of vancomycin and oritavancin to bind to
lipids extracted from S. aureus, wemonitored the ﬂuorescence intensity
of 8-anilino-1-naphthalene sulfonic acid (ANS), a probe that binds at the
membrane-water interface. InteractionbetweenANSand lipids induced
a substantial increase in probe quantum yield. Fig. 4 shows that the
ﬂuorescence signal increased as ANS was added in increasingFig. 2. Supported bilayer thickness (nm) as a function of time for lipid bilayers
incubated at room temperature in buffer (20 mMTris–HCl, 150 mMNaCl, pH 7.4) in the
presence of vancomycin (squares; closed symbols; 5.5 μM [8 mg/L]) or oritavancin
(circles; open symbols; 84 nM [0.15 mg/L]).concentrations to untreated vesicles, corresponding to the binding of
the probe, until a plateau was reached at high concentrations. Fig. 4
shows also that preincubation of the vesicles with vancomycin did not
markedly modify this signal, whereas it was signiﬁcantly increased in
vesicles preincubated with oritavancin. Cmax (the maximum concen-
tration of ANS bound to lipids), K (the association constant), and b (a
parameter that gives information of the cooperativity of the process),
were calculated after adjusting to Langmuir isotherm.With oritavancin,
all the three parameters were signiﬁcantly increased (Cmax: 1.57±
0.05 vs. 1.26±0.05; K: 55 μM−1×10−3±4 vs. 43 μM−1×10−3±3; b:
1.50±0.16 vs. 1.25±0.11). The calculated Δψ was+7±3mV. With
vancomycin, the Cmax values increased (0.56±0.08 vs. 0.30±0.06),
but no statistically signiﬁcant differences were observed for K (40±
14 μM−1×10−3 vs. 56±19 μM−1×10−3) or b (0.94±0.17 vs. 0.90±
0.30). Moreover, no positive value of Δψ was observed in the presence
of vancomycin.
3.4. Changes in bilayer packing and polarity at the glycerol backbone of
phospholipids (generalized polarization of Laurdan)
More data regarding the physical state of the lipids can be inferred
by measurement of the generalized polarization (GPex) of Laurdan. A
high GPex value is usually associated with a high bilayer packing and a
low polarity, whereas a low GPex value is associated with the opposite
[36]. The evaluation of GPex values with temperature was shown in
Fig. 5. As observed for biological membranes [43], no clear coexistence
of the gel and of the liquid crystalline phase was observed. In the
Fig. 4. Effect of vancomycin (top) and oritavancin (bottom) on ANS ﬂuorescence as a
function of free ANS. The closed and open symbols refer to data obtained in the absence
or in the presence of drug, respectively. Top: ANS was added to control liposomes
(closed symbols) or liposomes pre-exposed to vancomycin (60 nM; open symbols).
Bottom: ANS was added to control liposomes (closed symbols) or to liposomes pre-
exposed to oritavancin (60 nM; open symbols). The total lipid concentration was
50 μM. Each value is the average of three independent experiments. Statistical analysis
(2-ways ANOVA comparing all data points): the p values versus control are 0.517
andb0.0001 for vancomycin and oritavancin, respectively.
Fig. 5. Effect of vancomycin (top) and oritavancin (bottom) on generalized polarization
(GPex) values for Laurdan in vesicles made of S. aureus lipids as a function of
temperature. The closed and open symbols refer to data obtained in absence or
presence of drug (60 nM), respectively. The excitation wavelength was ﬁxed at 340 nm
and emission intensities at 440 nm (gel phase) and 490 nm (liquid crystalline phase).
Each value is the average of three independent experiments. Statistical analysis (2-
ways ANOVA comparing all data points): the p values vs. control areb0.0001.
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temperature similarly to controls. Both vancomycin and oritavancin
induced a signiﬁcant effect (pb0.0001) dependent on the nature of
the antibiotic. Vancomycin induced a shift to slightly lower values
with a decrease of the Tm values from 23.6±1.0 °C to 20.1±0.9 °C
(pb0.02). In contrast, oritavancin markedly shifted GPex values
towards higher values with a variation of Tm from 19.9±0.6 °C to
22.3±0.7 °C (pb0.02).3.5. Changes in the hydrophobic core of bilayers (DPH ﬂuorescence
anisotropy)
To determine the effect of vancomycin and oritavancin on the acyl
chain ordering in the hydrophobic core region of the membrane of
liposomes, we measured the change in ﬂuorescence anisotropy of the
hydrophobic probe DPH upon temperature increase. As shown in
Fig. 6, the DPH-steady state ﬂuorescence anisotropy intensity
gradually declined as the temperature increased from 3 to 37 °C. As
for GPex determinations, no sharp phase transitions were observed
and a continuous decrease of depolarization intensities with increas-
ing temperature was seen. Compared to their respective control, no
gross effect of vancomycin or oritavancin was observed. However,
statistical analysis showed that vancomycin induced a slight increase
of the DPH-steady state ﬂuorescence depolarization intensities upon
increasing temperatures (pb0.001) (Fig. 6, upper panel) whereas
oritavancin had the opposite effect (p=0.0005) (Fig. 6, lower panel).
The Tm values were slightly increased with vancomycin (15.9±0.4 °C
vs. 19.0±0.8 °C; pb0.005) and not signiﬁcantly modiﬁed with
oritavancin (12.5±1.3 °C vs. 11.0±2.0 °C; pb0.02).Fig. 6. Effect of vancomycin (top) and oritavancin (bottom) on ﬂuorescence anisotropy
(r) of DPH in lipid vesicles upon increasing temperatures. The closed and open symbols
refer to data obtained in the absence or in the presence of drug, respectively. DPH was
incorporated at a molar ratio to the lipids of 1:300. Labeled liposomes were incubated
with drugs (60 nM) at 37 °C for 30 min. Liposomes were then brought to 3 °C, stabilized
at this temperature during 15 min before starting the measurements, during which the
samples were heated to 40 °C at a rate of 16 °C/h. Data are representative of
experiments that were reproduced three times. Statistical analysis (2-ways ANOVA
comparing all data points): p value vs. control:b0.0001 for vancomycin and 0.0005 for
oritavancin).
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and LysylDOPG:POPG:POPE vesicles
To further characterize the speciﬁc role played by individual lipids
on the effects of glycopeptides at the level of glycerol backbone and
deeper in the bilayer, we reproduced these experiments using
(LysylDOPG:POPG:POPE (0.5:8:4) and CL:POPE (2:8) liposomes.
Investigating the role of cardiolipin (an anionic lipid) and lysylpho-
sphatidylglycerol (a positively charged lipid) was of particular
interest since a decrease in the net negative charge of the cell
envelope is a strategy used by numerous bacteria, including S. aureus,
to modulate their afﬁnity for cationic antibiotic microbial molecules
[44]. Moreover, we showed previously that the increase of membrane
permeability induced by oritavancin is maximal in the presence of
cardiolipin [23]. Thus, we examined, and show in Fig. 7, the effect of
oritavancin on Laurdan generalized polarization (left panel) and
anisotropy ﬂuorescence of DPH (right panel) on CL:POPE (2:8) (top)
and on LysylDOPG:POPG:POPE (0.5:8:4) (bottom) vesicles.
First, in contrast to what was observed with lipids extracted from
S. aureus, and as largely reported in literature, the thermotropicbehavior
of synthetic and/or deﬁned lipids clearly showed the appearance of
gel and liquid phases with a deﬁned Tm. This is well illustrated for
LysylDOPG:POPG:POPE (Fig. 7, lower panels). In the presence of
cardiolipin, a natural lipid for which the length and the degree of
unsaturation are not deﬁned, the phase separation was less marked,
probably due to the variability of the length as well as the degree of
insaturation of the acyl chains of cardiolipin. Second, when oritavancin
was added to CL:POPE liposomes, we conﬁrmed its ability to induce an
increase of GPex values, especially at temperatures around the Tm with
an increase from 13.5±1.7 to 15.5±1.1 (pb0.001). No effect was
observed at low and high temperatures. In contrast, when oritavancin
was added to LysylDOPG:POPG:POPE liposomes, a slight decrease
of GPex values was observed with a decrease of Tm from 23.0±0.4 to
21.2±0.3 (pb0.001). As observedwith vesiclesmade of lipids extractedFig. 7. Effect of oritavancin (60 nM) on generalized polarization values (GPex) for Laurdan (le
CL:POPE (top) and lysylDOPG:POPG:POPE (bottom) upon increasing temperatures. Stati
areb0.0001 except for oritavancin in Laurdan assay with LysylDOPG:POPG:POPE (pb0.0114from S. aureus, oritavancin very slightly affected the ﬂuorescence
polarization values of DPH.
4. Discussion
The present study expands over our previous observations
concerning the ability of oritavancin, a novel lipoglycopeptide antibiotic
with marked bactericidal activity against S. aureus and other Gram-
positive bacteria, to destabilize model membrane bilayers (liposomes)
when these contain a large proportion of acidic phospholipids such as
phosphatidylglycerol and cardiolipin [23]. The present study aimed at
gaining additional insight into the molecular mechanism of this
phenomenon by (i) using lipids extracted from the target bacteria
themselves; (ii) examining the inﬂuence exerted by oritavancin at the
levels of glycerol backbone and the hydrophobic core of the bilayers;
(iii) systematically comparing oritavancinwith the prototype glycopep-
tides antibiotic vancomycin at concentrations that are close to those at
which these drugs exert a bactericidal effect towards S. aureus in
conventional microbiological studies.
AFM provides a true three-dimensional map of the surface of the
samples at a submicron scale togetherwith the capacity to analyze them
as immersed in deﬁned ﬂuids [42]. Our observations provide direct
evidence for the ability of oritavancin, but not of vancomycin, to induce
holes in membranes, which is conﬁrmed by the results of the calcein
release experiments. The mechanisms responsible for membrane
permeabilization are complex but three main ones have been proposed
(see [45] for review). The ﬁrst is related to the presence of local
microscopic regions of disorder or defects enhanced by drugs. The
enhancement of permeability would, therefore, be due to instability of
boundary regions around the interdigitated structure domains, charac-
terized by a thinner structure and more rigid hydrocarbon regions than
its non-interdigitated counterpart. The two othermechanisms involved
in membrane permeabilization are the partitioning of the drug
monomer into the lipid bilayer and oligomerization as well as theft) or ﬂuorescence anisotropy polarization (r) for DPH (right) in phospholipid vesicles of
stical analysis (2-ways ANOVA comparing all data points): all p values vs. controls
) and DPH experiment with CL:POPE (pb0.0740).
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thebindingof thedrug to the outermembrane. The latter feature is a key
parameter for driving shape changes and curvature stress. AFM could
not directly visualize oritavancin binding. In future work, it would be
interesting to examine whether friction images could reveal any
contrast associated with oritavancin binding.
In the present work, we characterize the molecular interactions
between oritavancin and lipids, using ﬂuorescence approaches to
determine in one hand the ability of oritavancin to bind to lipid
membranesmimicking the bilayer of S. aureus, and, in the other hand, to
know at which level oritavancin most likely interacts in the bilayer
(glycerol backbone vs. hydrocarbon chains). This was made by using
ANS, Laurdan and DPH. ANS is a negatively charged dye with a higher
ﬂuorescence yield in lipid than in aqueous environments. Being
repulsed by the membrane, an increase in its binding must be inter-
preted as a decrease of the global negative charges of the surface of the
bilayer. This property has been used to characterize the interaction of
drugs [34,46], bactericidal peptides [47], or cytochrome c [48,49] with
lipids, and to study intracellular lipid-binding proteins [50]. Laurdan,
which localizes at∼11.4 Å from the bilayer center [51], shows
ﬂuorescence excitation and emission spectra that are affected by the
lipid packing, the rate of dipolar relaxation and the hydrophilic/
hydrophobic character of its surrounding environment [36,38,43,52]. It
has been successfully used to study the interactions of peptides [53,54],
including toxins [55,56] or proteins [57], with lipid bilayers. DPH is a an
hydrophobic probe widely used for testing the ﬂuidity of the inner core
of the bilayer [39–41]. Interpreting our data with oritavancin, in
comparison with vancomycin, must take into account that oritavancin
is bothmore cationic (due to the presence of an epivancosaminemoiety
absent in vancomycin), and more hydrophobic (with calculated log P
and log DpH7 of 4.10 and−3.43 vs.−1.44 and−4.70 for vancomycin).
We see that oritavancin (i) markedly increases the binding of ANS and
modiﬁes the interactions of Laurdanwith the adjacentwatermolecules,
while having only a very modest effect on the ﬂuorescence polarization
of DPH. Vancomycin had only limited effects with respect to ANS and
Laurdan, and its inﬂuence on theﬂuorescence polarization of DPH is also
quite modest and in the opposite direction to that of oritavancin.
Together, these experiments strongly suggest that oritavancin binds to
the bilayers (thereby reducing its negative surface charge) and interacts
at the level of the glycerol backbone by hindering the accessibility of
water and rigidifying the lipid bilayer. Oritavancin, however, would not
markedly affect the deeper domains of the bilayer. Vancomycin is
without major effect on either domain of the bilayer, due to its lack of
binding under the in vitro conditions used here. Thus, ordering at the
level of glycerol backbone, which is the ﬁrst of the mechanisms
discussed above [45], could be critical for subsequent
lipid permeabilization. This conclusion is consistent with our previous
studies with model POPG:POPE bilayer membranes that showed a
high propensity of oritavancin to interact through hydrogen bonds
with phosphate and carbonyl oxygen atoms as well as a much denser
packing of chain atoms in the near surface regions of the hydrocarbon
core [23].
The membranes prepared here were made of a mixture of lipids
extracted from S. aureus. The major lipids present are phosphatidyl-
glycerol, cardiolipin and lysylphosphatidylglycerol, a lipid synthe-
sized by the membrane protein MprF [58,59]. These differ by their
structure, charge, non-lamellar propensity and cross-sectional area.
These lipids can also exist in a variety of organized supramolecular
structures and interact dynamically to form transient arrangements.
The use of natural lipid extracts explains the lack of sharp transition
between the gel and liquid crystal phase compared to what is seen
liposomes made of synthetic lipids. Similarly, the cohesive effect of
oritavancin on GPex was smaller on vesicles prepared from lipid
extracts as compared to those composed of CL:POPE, and the calcein
release was less important [23]. Differences in membrane perme-
ability properties have already been observed when comparingvesicles made of lipids extracted from bacteria to those made of
pure lipids or binary mixtures of phospholipids [60]. Further
experiments will need to examine the reasons for these differences.
For vesicles made of LysylDOPG:POPG:POPE, the decrease of the
negative charge of the membrane probably explains the absence of
major effect of oritavancin on GPex and ﬂuorescence anisotropy
values. Accordingly, S. aureus mprF mutants show a decreased
susceptibility to cationic antimicrobial peptides of the innate immune
system and vancomycin [61] and to the membrane permeabilizing
antibiotic daptomycin [62].
Together, our data conﬁrm the interactions of oritavancin with S.
aureus membrane lipids and its capacity to permeabilize lipid vesicles
made of these lipids at concentrations at which the drug is known to
exert a bactericidal effect on bacteria. It is, therefore, tempting to
speculate that this may be the basis of its marked and fast bactericidal
effect [63], including against non-growing bacteria [15], making it quite
distinct from vancomycin in this context. As discussed previously [23],
the speciﬁcity of oritavancin action towards bacteria vs. eukaryotic cells,
probably stems from (i) the presence of free D-Ala-D-Ala motifs at the
inner face of the cell wall (peptidoglycan) that allows an anchoring the
drug close to the bacterial membrane (see model in [1]) and (ii) the
abundance in S. aureus of negatively charged lipids (phosphatidylgly-
cerol and cardiolipin) that are critical for interaction of thedrugwith the
bilayer but are rare in the eukaryotic pericellular membrane. Such
differences in drug–lipid membrane interactions have also been
reported for a hydrophobic membrane-binding peptide antibiotic,
NK2, that regulates the structure of the membrane and kills bacterial
but not human cells [64] or for cecropin-melittin antimicrobial hybrid
peptide BP100 [65]. The present data do not exclude that other mech-
anisms, such as inhibition of transglycosylase activity [66] or additional
bindingwith cell wall pentaglycyl bridges [67,68], could also contribute
to the antibacterial effects of oritavancin. However, none of them
explains as such the intense bactericidal activity of oritavancin at the
low concentrations at which it can be observed.
In conclusion, we have provided here a comprehensive study of the
interaction of oritavancin, a novel lipoglycopeptide endowed with
potent antimicrobial activity, with phospholipid bilayers prepared with
lipids extracted from S. aureus. We elucidated fundamental issues such
as the speciﬁc interaction of oritavancin at the level of the glycerol
backbone and the hydrophobic domain of the bilayer by monitoring
Laurdan excitation GPex and ﬂuorescence anisotropy of DPH, respec-
tively. Oritavancin induces higher GPex values and increase of transition
temperature indicating a membrane in a more ordered structure at the
level of the glycerol backbone of the lipid bilayer where Laurdan is
localized. In the non-polar environment where DPH incorporates,
oritavancin slightly decreases the ﬂuorescence depolarization intensi-
ties, suggesting a modest increase in ﬂuidity. Altogether, these effects
could be related to the ability of oritavancin antibiotic to induce holes,
erosion of the edges and decrease of the thickness of the supported lipid
bilayers as well as to increase membrane permeabilization. Progress in
understanding the lipid–drug interactions appears to be of crucial
importance to understand the mechanisms involved in antibacterial
activity of new compounds.Acknowledgments
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